 |
Recombinant T-cell receptor ligand |
|---|---|
| Trade Name | |
| Orphan Indication | Multiple sclerosis patients who are both HLA-DR2 positive and autoreactive to myelin oligodendrocyte glycoprotein residues 35-55 |
| USA Market Approval | USA |
| USA Designation Date | 2003-05-02 00:00:00 |
| Sponsor | Artielle ImmunoTherapeutics, Inc.;9020 SW Washington Square Road, Suite 450;Tigard,, Oregon, 97223 |
